ARA-290
December 5, 2023Incremental
4/10
Purrptide digest
ARA-290 is engineered from erythropoietin (EPO) — but stripped of the part that thickens your blood, keeping only the tissue-protective signaling. That matters because EPO-boosting drugs carry serious cardiovascular risk from increased blood viscosity. This peptide was designed specifically to avoid that. Early trials focus on neuropathic pain and nerve protection, leveraging EPO's lesser-known tissue-repair signaling pathway rather than its famous blood-boosting one.
What this means for you
🏃
If you care about weight/health
Early-stage and trial-only for now, but the neuropathic pain angle is one to watch if you deal with nerve-related discomfort.
🩺
If you're a clinician
Separates EPO's tissue-protective signaling from its hematopoietic effect — a cleaner safety profile than traditional EPO-boosting agents.
🔬
If you're a researcher
The split between EPO's blood-cell-stimulating and cytoprotective receptor pathways is the core mechanistic insight worth digging into.
💸
If you follow biotech
A non-hematopoietic EPO derivative opens therapeutic doors that the cardiovascular risk of regular EPO drugs has kept closed.
HE
Heij et al.
Araim Pharmaceuticals
For the nerds
Erythropoietin-derived peptide ARA290 for neuropathic pain in sarcoidosis
Molecular Medicine · DOI: 10.2119/molmed.2012.00018
Read full paper on PubMed →